[News Brief] HealthTechX Asia 2026 to Spotlight Digital Healthcare Innovation
HealthTechX Asia 2026, scheduled for 6–7 May 2026 in Singapore, will convene healthcare providers, technologists, innovators and stakeholders to explore…
Asia PR
[News Brief] Chinese Medicines Increasingly Reach Global Health Market
A report from China’s State Council Information Office shows that Chinese-made medicines and medical devices are gaining a stronger foothold…
[News Brief] C&R Research Strengthens Clinical Trial Capabilities in Indonesia
C&R Research, a South Korean contract research organisation (CRO), is expanding its clinical trial operations in Indonesia as part of…
[News Brief] Kerry Releases 2026 Supplement Taste Charts
Kerry has published its 2026 Taste Charts, identifying emerging flavour trends for the supplements and sports nutrition sectors. This summary…
[News Brief] GSK Receives Japanese Approval for Depemokimab
Japan’s Ministry of Health, Labour and Welfare has approved GSK’s depemokimab (Exdensur) as an add-on treatment for certain types of…
[News Brief] Hyperfine Receives Indian Regulatory Approval for Swoop MRI System
Hyperfine, Inc. has secured regulatory clearance from India’s Central Drugs Standard Control Organisation (CDSCO) for its “Swoop” portable brain MRI…
[News Brief] Lunit and Daiichi Sankyo Partner for AI‑Driven Biomarker Discovery and Translational Oncology Research
Lunit has announced a collaboration with Daiichi Sankyo to advance research in AI‑driven biomarker discovery and translational oncology. This summary…
[News Brief] Linaprazan Glurate Included in China’s National Reimbursement List
Cinclus Pharma Holding AB’s drug linaprazan glurate has been included in China’s 2025 National Reimbursement Drug List (NRDL) ahead of…
[News Brief] Gene Solutions Introduces SPOT-MAS Multi-Cancer Screening in Taiwan
Gene Solutions, in partnership with Gene Health, has launched SPOT-MAS in Taiwan, an AI-driven multi-cancer early detection (MCED) solution designed…
[News Brief] Mirxes Lists on HKEX as Southeast Asia’s First Biotech Unicorn
Mirxes listed on the Hong Kong Stock Exchange Main Board on 23 May 2025, reaching a market capitalisation of HK$8.29…